A nonprofit group’s Chagas drug beat out Martin Shkreli's old rival to FDA OK, valuable PRV
The FDA has approved a new drug for Chagas disease, but one of Martin Shkreli’s former biotechs — which set its sights on Chagas — isn’t the one benefiting from the marketing OK. And Shkreli’s successors say they now have to switch up their game plan after the rival group snagged the valuable priority review voucher that came with the first OK, blasting their share price.
The nonprofit drug development organization Drugs for Neglected Diseases initiative (DNDi), along with the pharmaceutical company Chemo Group and the nonprofit foundation Mundo Sano set out a year ago to register the drug in areas where its needed, including the US.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.